Cannabis Science Inc (OTCMKTS:CBIS) has been around longer than any other Cannabis company, and we’ve been following the trading action in these shares since 2012. I really cannot think of a more representative stock that has been around for the starts and stops more than CBIS. The company is listed on the OTCBB Pinksheets which essential means they are in the non-filing category, but that doesn’t deter investors to flock to Cannabis Science when news about the industry grabs hold in the media cycle. A look at a longer term chart shows the rise in prices and volume dating back to April 2012, February 2014 when you had rising prices and subsequent pullbacks in the sector.
Shares logically rallied during the election cycle in November 2016 where CBIS have a 4x move on huge volume. Cannabis Science seems to be a retail investment for many who wanted to jump on the Cannabis train, and owned shares previously in the space.
Cannabis Science Inc (OTCMKTS:CBIS) specializes in the development of cannabis-based medicines, and recently announced the anticipated delivery of the first of pre-designed greenhouses with full tracking and reporting protocols to be delivered this week for the California and Nevada operations.
“Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed product readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage,” stated CMO Dr. Allen Herman.
Find out when $CBIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
CBIS, Inc. said it has received several hundred emails inquiring about the timing of clinical research and the availability of treatment options. These inquiries cover the management of pain, peripheral neuropathies, cancer, and COPD. All inquiries are entered into our in-house database and we will be responding to each person as each targeted observational study officially commences. The studies will include some of the over 500 cannabinoids that have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis. Common plant cannabinoids (phytocannabinoids) include: tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). The pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis. Our in-house database will form the basis of patient-centered outcomes research (PCOR) for a variety of critical conditions.
CBIS will then develop protocols for an international consortium of US, South African, and European universities and research institutions. This consortium will develop research protocols for animal studies and clinical trials for several critical clinical ailments concurrently.
The Cannabis Science Research Laboratory will have principal investigators at each partner institution and will work closely with CBIS leadership. Our initial animal studies will focus on cancers, and our clinical trials will concentrate on Cancers, PTSD, pain management, HIV/AIDS, and neurological conditions including sleep disorders. CBIS will then add other targeted ailments for clinical trials as the demand and need is identified in each jurisdiction. Each country that we collaborate in will ensure that the research is done within the approval guidelines for that country and follows the approval guidelines for the US Food and Drug Administration providing nationwide federal government approvals.
Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively. On January 3, 2017, Cannabis Science entered into a CRA with Dana-Farber, one of the world’s leading cancer centers. Under the terms of the CRA, Cannabis Science and Dana-Farber will jointly investigate and develop use of cannabinoids to treat various forms of cancers.
“I am excited about Cannabis Science’s relationship with Dana-Farber. When I first met Wilfred Ngwa, PhD, Director of Global Health Catalyst at Harvard Medical School and Principal Investigator for the CRA, we immediately realized potential synergies on cancer research interests, and the potential to collaborate to develop cannabinoid-based medicines to treat cancer and control cancer symptoms with minimal side-effects,” stated Dabney.
These important steps and the size of the shareholder base makes Cannabis Science one of the widely held names in the sector. CBIS is currently trading at market cap of nearly a $200M, which is astounding for this developing industry, and a look closer sees the company has 2 billion+ shares out making it one to watch anytime the Cannabis Sector comes in focus. For continuing coverage on shares of $CBIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!